3D/L Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

3D/L Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,208	Closed	-$234K	–	69
2023 Q3	$234K	Buy	3,208 +42	+1%	+$3.35K	0.08%	75
2023 Q2	$263K	Buy	3,166 +35	+1%	+$2.93K	0.08%	80
2023 Q1	$239K	Sell	3,131 -304	-9%	-$25.2K	0.06%	94
2022 Q4	$285K	Sell	3,435 -94	-3%	-$7.61K	0.08%	78
2022 Q3	$280K	Sell	3,529 -23	-0.6%	-$1.94K	0.08%	76
2022 Q2	$264K	Buy	+3,552	New	+$267K	0.07%	83

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

3D/L Capital Management's XBI Position: Q4 2023 in Review

3D/L Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 3,208 shares — an estimated $234K sold.

3D/L Capital Management first reported a position in XBI in Q2 2022 and held it in 6 quarters. The position peaked at $285K in Q4 2022. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

3D/L Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
3D/L Capital Management sold 3,208 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $234K.
3D/L Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 6 quarters.
3D/L Capital Management's State Street SPDR S&P Biotech ETF position peaked at $285K in Q4 2022.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on 3D/L Capital Management's 13F filing for Q4 2023.